Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Survivin inhibitor

DRUG CLASS:

Survivin inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Glioblastoma	No biomarker	Glioblastoma	SVN53-67/M57-KLH peptide vaccine Sensitive: B - Late Trials SVN53-67 / M57-KLH peptide vaccine Sensitive : B	SVN53-67/M57-KLH peptide vaccine Sensitive: B - Late Trials SVN53-67 / M57-KLH peptide vaccine Sensitive : B
BIRC5 expression	Diffuse Large B Cell Lymphoma	BIRC5 expression	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C2 – Inclusion Criteria pembrolizumab + MVP-S Sensitive : C2	pembrolizumab + MVP-S Sensitive: C2 – Inclusion Criteria pembrolizumab + MVP-S Sensitive : C2
PD-L1 expression	Diffuse Large B Cell Lymphoma	PD-L1 expression	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials pembrolizumab + MVP-S Sensitive : C3	pembrolizumab + MVP-S Sensitive: C3 – Early Trials pembrolizumab + MVP-S Sensitive : C3
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials pembrolizumab + MVP-S Sensitive : C3	pembrolizumab + MVP-S Sensitive: C3 – Early Trials pembrolizumab + MVP-S Sensitive : C3
DNMT3A mutation	Acute Lymphocytic Leukemia	DNMT3A mutation	Acute Lymphocytic Leukemia	PC-002 Sensitive: D – Preclinical PC-002 Sensitive : D	PC-002 Sensitive: D – Preclinical PC-002 Sensitive : D